FLT3 mutations in myeloid sarcoma

British Journal of Haematology
M Ali Ansari-LariKathleen M Murphy

Abstract

Myeloid sarcoma is an extramedullary tumour that typically occurs in the setting of acute myeloid leukaemia (AML), or myeloproliferative disorders. In AML, two types of mutations in Fms-like tyrosine kinase 3 (FLT3) have been described; internal tandem duplications (ITD) and point mutations at aspartic acid residue 835 (D835). We analysed 24 myeloid sarcoma specimens from 20 patients for FLT3 ITD and D835 mutations. FLT3 ITD mutations were identified in three of 20 cases (15%); no D835 mutations were identified. The ITD inserts ranged in size from 33 to 198 base pairs (bp) and represented approximately 20-40% of the FLT3 alleles. Two cases showed discordance in FLT3 ITD mutational status. In one case, the leukaemia specimen was positive for a FLT3 ITD mutation and the myeloid sarcoma specimen was negative. In the second case, the myeloid sarcoma was positive for a FLT3 ITD mutation at diagnosis, but negative in subsequent relapse samples. Our findings suggest that small molecule inhibitors of FLT3 may be useful therapeutic agents for treatment of myeloid sarcomas-containing FLT3 mutations, however, the potential for discordance between the leukaemia and myeloid sarcoma, necessitates that the myeloid sarcoma tumour itself be ana...Continue Reading

References

Feb 1, 1991·American Journal of Hematology·S H AdvaniC N Nair
Dec 15, 1986·Cancer·J M MeisJ T Manning
Feb 1, 1981·American Journal of Clinical Pathology·L PetersonR D Brunning
Jun 1, 1994·Leukemia & Lymphoma·S A Ridge, L M Wiedemann
Nov 25, 2000·British Journal of Haematology·F M Abu-DuhierJ T Reilly
Jul 10, 2001·British Journal of Haematology·F M Abu-DuhierJ T Reilly
Apr 15, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·Mohammad Hasan SheikhhaJohn Ahman Liu Yin
Aug 16, 2003·Annals of Hematology·A ZebischH Sill
Sep 13, 2003·Leukemia·M Levis, D Small
Oct 7, 2003·Journal of Pediatric Hematology/oncology·Kathryn E DusenberyWilliam G Woods
Dec 4, 2003·Expert Opinion on Investigational Drugs·Mark Levis, Donald Small

❮ Previous
Next ❯

Citations

Dec 16, 2006·Leukemia & Lymphoma·Semra PaydasMelek Ergin
May 12, 2015·Expert Review of Hematology·Adarsh VennepureddyTerenig Terjanian
Jul 18, 2015·American Journal of Clinical Pathology·Carla S Wilson, L Jeffrey Medeiros
Jun 4, 2011·Hematological Oncology·Batia AvniOra Paltiel
Sep 3, 2011·International Journal of Laboratory Hematology·J M KlcoJ L Frater
Nov 28, 2013·Journal of Cutaneous Pathology·Amir AboutalebiRosalynn M Nazarian
Apr 21, 2016·Blood Reviews·Melhem SolhAsad Bashey
Apr 23, 2016·The American Journal of Medicine·Daniela DörfelMarius Horger
Jul 29, 2011·Blood·Richard L BakstJoachim Yahalom
Oct 1, 2011·Therapeutic Advances in Hematology·Batia Avni, Maya Koren-Michowitz
Nov 18, 2017·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Michael OertelHans Theodor Eich
Feb 2, 2019·Leukemia & Lymphoma·Ludovic FouilletPascale Flandrin-Gresta
Jan 7, 2020·Current Opinion in Hematology·Omar A Shahin, Farhad Ravandi
Oct 12, 2016·Journal of Hematology & Oncology·Jie XuSai-Juan Chen
Jan 30, 2021·International Journal of Hematology·Meng ShanDepei Wu
Nov 25, 2020·Human Pathology·Nancy Y GreenlandLinlin Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.